Shinji S, Yamada T, Matsuda A, Uehara K, Yokoyama Y, Takahashi G, Iwai T, Miyasaka T, Kanaka S, Hayashi K, Yoshida H. Clinical utility of a novel concentrated enteral formula in patients undergoing colorectal cancer surgery: A randomized controlled trial. World J Gastrointest Surg 2025; 17(11): 112557 [DOI: 10.4240/wjgs.v17.i11.112557]
Corresponding Author of This Article
Seiichi Shinji, MD, PhD, Associate Professor, FACS, Department of Gastroenterological Surgery, Nippon Medical School, No. 1-1-5 Sendagi, Bunkyo-ku 113-8603, Tokyo, Japan. s-shinji@nms.ac.jp
Research Domain of This Article
Surgery
Article-Type of This Article
Randomized Controlled Trial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nov 27, 2025 (publication date) through Nov 25, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Surgery
ISSN
1948-9366
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Shinji S, Yamada T, Matsuda A, Uehara K, Yokoyama Y, Takahashi G, Iwai T, Miyasaka T, Kanaka S, Hayashi K, Yoshida H. Clinical utility of a novel concentrated enteral formula in patients undergoing colorectal cancer surgery: A randomized controlled trial. World J Gastrointest Surg 2025; 17(11): 112557 [DOI: 10.4240/wjgs.v17.i11.112557]
World J Gastrointest Surg. Nov 27, 2025; 17(11): 112557 Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.112557
Clinical utility of a novel concentrated enteral formula in patients undergoing colorectal cancer surgery: A randomized controlled trial
Seiichi Shinji, Takeshi Yamada, Akihisa Matsuda, Kay Uehara, Yasuyuki Yokoyama, Goro Takahashi, Takuma Iwai, Toshimitsu Miyasaka, Shintaro Kanaka, Koki Hayashi, Hiroshi Yoshida
Seiichi Shinji, Takeshi Yamada, Akihisa Matsuda, Kay Uehara, Yasuyuki Yokoyama, Goro Takahashi, Takuma Iwai, Toshimitsu Miyasaka, Shintaro Kanaka, Koki Hayashi, Hiroshi Yoshida, Department of Gastroenterological Surgery, Nippon Medical School, Bunkyo-ku 113-8603, Tokyo, Japan
Author contributions: Shinji S performed data analysis and wrote the paper; Yoshida H provided statistical guidance and supervised the study; Shinji S and Yoshida H conceptualized and designed the research; Shinji S, Yamada T, Matsuda A, Uehara K, Yokoyama Y, Takahashi G, Iwai T, Miyasaka T, Kanaka S, and Hayashi K screened patients and acquired clinical data. All authors critically revised the manuscript for important intellectual content.
Institutional review board statement: This study was reviewed and approved by the Ethics Review Committee of the Nippon Medical School Hospital, No. M-2022-048 (Tokyo, Japan).
Informed consent statement: All individuals who participated in this study provided written informed consent before enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Seiichi Shinji, MD, PhD, Associate Professor, FACS, Department of Gastroenterological Surgery, Nippon Medical School, No. 1-1-5 Sendagi, Bunkyo-ku 113-8603, Tokyo, Japan. s-shinji@nms.ac.jp
Received: July 31, 2025 Revised: August 14, 2025 Accepted: September 9, 2025 Published online: November 27, 2025 Processing time: 117 Days and 22.1 Hours
Abstract
BACKGROUND
Compared to standard hospital meals, nutritional intervention using recovery K5 (RK5), a concentrated liquid diet, offers a comprehensive immunonutritional profile, suggesting its potential effectiveness in preventing surgical site infections (SSIs) after gastrointestinal surgery.
AIM
To investigate the usefulness of RK5 in patients undergoing elective colorectal cancer surgery, focusing on postoperative infections and nutritional status.
METHODS
This single-center, open-label, randomized, parallel-group comparative trial was conducted at Department of Gastrointestinal Surgery, Nippon Medical School Hospital, between February 2023 and August 2024. Forty patients with colorectal cancer were randomly assigned in a 1:1 ratio to either the nutritional intervention or the control group. The intervention group received 800 kcal/day of RK5 administered orally instead of breakfast and dinner (400 kcal per serving) 2 days prior to surgery, whereas the control group received only standard meals. Postoperative infection, nutritional status, and bowel habits were assessed.
RESULTS
No cases of remote infection were observed. SSIs occurred in one of the 17 patients (5.9%) in the intervention group and six of the 18 patients (33.3%) in the control group, with an odds ratio of 0.125 (95% confidence interval: 0.013-1.181, P = 0.0695). Energy intake and percentage of target energy intake were significantly higher in the intervention group. No significant differences were observed between the two groups regarding nutritional status, bowel movement frequency, or the incidence of diarrhea.
CONCLUSION
Supplemental nutrition using RK5 may help prevent SSIs in patients undergoing elective colorectal cancer surgery and should be considered as a potential option for perioperative nutritional management.
Core Tip: This study assessed the clinical utility of recovery K5 (RK5), a concentrated liquid formula, in patients undergoing elective colorectal cancer surgery. Patients receiving RK5 in addition to standard meals were compared with those receiving standard meals alone. RK5 supplementation improved target energy intake achievement and showed a trend toward reduced surgical site infections.
